메뉴 건너뛰기




Volumn 35, Issue 2, 2013, Pages 119-127

Pharmacotherapy of autism spectrum disorders

Author keywords

Autism spectrum disorders; Maladaptive behaviors; Novel targeted treatments; Pharmacotherapy

Indexed keywords

ARIPIPRAZOLE; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; ESCITALOPRAM; ETIRACETAM; FLUOXETINE; GUANFACINE; HALOPERIDOL; LAMOTRIGINE; METHYLPHENIDATE; OLANZAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; VALPROATE SEMISODIUM;

EID: 84872409803     PISSN: 03877604     EISSN: 18727131     Source Type: Journal    
DOI: 10.1016/j.braindev.2012.03.015     Document Type: Review
Times cited : (43)

References (86)
  • 1
    • 73149102059 scopus 로고    scopus 로고
    • Autism and Developmental Disabilities Monitoring Network Surveillance Year 2006 Principal Investigators, Centers for Disease Control and Prevention (CDC). Prevalence of autism spectrum disorders - Autism and Developmental Disabilities Monitoring Network, United States, MMWR Surveill Summ
    • Autism and Developmental Disabilities Monitoring Network Surveillance Year 2006 Principal Investigators, Centers for Disease Control and Prevention (CDC). Prevalence of autism spectrum disorders - Autism and Developmental Disabilities Monitoring Network, United States, MMWR Surveill Summ 2009; 58:1-20.
    • (2009) , vol.58 , pp. 1-20
  • 3
    • 77952091222 scopus 로고    scopus 로고
    • Understanding and determining the etiology of autism
    • Currenti S.A. Understanding and determining the etiology of autism. Cell Mol Neurobiol 2010, 30:161-171.
    • (2010) Cell Mol Neurobiol , vol.30 , pp. 161-171
    • Currenti, S.A.1
  • 5
    • 65649129003 scopus 로고    scopus 로고
    • How can early, intensive training help a genetic disorder?
    • Altemeier W.A., Altemeier L.E. How can early, intensive training help a genetic disorder?. Pediatr Ann 2009, 38:167-170.
    • (2009) Pediatr Ann , vol.38 , pp. 167-170
    • Altemeier, W.A.1    Altemeier, L.E.2
  • 6
    • 84872370133 scopus 로고    scopus 로고
    • An Italian prospective study on autism treatment: the earlier, the better?
    • Vivanti G., Manzi B., Benvenuto A., Battan B., Curatolo P. An Italian prospective study on autism treatment: the earlier, the better?. Autism 2011, 10.4172/auo.1000102.
    • (2011) Autism
    • Vivanti, G.1    Manzi, B.2    Benvenuto, A.3    Battan, B.4    Curatolo, P.5
  • 7
    • 75649107225 scopus 로고    scopus 로고
    • Novel and emerging treatments for autism spectrum disorders: a systematic review
    • Rossignol D.A. Novel and emerging treatments for autism spectrum disorders: a systematic review. Ann Clin Psychiatry 2009, 21:213-236.
    • (2009) Ann Clin Psychiatry , vol.21 , pp. 213-236
    • Rossignol, D.A.1
  • 8
    • 2342417739 scopus 로고    scopus 로고
    • Pharmacologic treatment of autism
    • Palermo M.T., Curatolo P. Pharmacologic treatment of autism. J Child Neurol 2004, 19:155-164.
    • (2004) J Child Neurol , vol.19 , pp. 155-164
    • Palermo, M.T.1    Curatolo, P.2
  • 9
    • 60249083550 scopus 로고    scopus 로고
    • Pharmacologic treatment for the core deficits and associated symptoms of autism in children
    • West L., Waldrop J., Brunssen S. Pharmacologic treatment for the core deficits and associated symptoms of autism in children. J Pediatr Health Care 2009, 23:75-89.
    • (2009) J Pediatr Health Care , vol.23 , pp. 75-89
    • West, L.1    Waldrop, J.2    Brunssen, S.3
  • 10
    • 82755194994 scopus 로고    scopus 로고
    • Assessment of health-related quality of life among primary caregivers of children with autism spectrum disorders
    • Khanna R., Madhavan S.S., Smith M.J., Patrick J.H., Tworek C., Becker-Cottrill B. Assessment of health-related quality of life among primary caregivers of children with autism spectrum disorders. J Autism Dev Disord 2011, 41:1214-1227.
    • (2011) J Autism Dev Disord , vol.41 , pp. 1214-1227
    • Khanna, R.1    Madhavan, S.S.2    Smith, M.J.3    Patrick, J.H.4    Tworek, C.5    Becker-Cottrill, B.6
  • 11
    • 77955863445 scopus 로고    scopus 로고
    • Health-related quality of life in children with autism spectrum disorders: results from the autism treatment network
    • Kuhlthau K., Orlich F., Hall T.A., Sikora D., Kovacs E.A., Delahaye J., et al. Health-related quality of life in children with autism spectrum disorders: results from the autism treatment network. J Autism Dev Disord 2010, 40:721-729.
    • (2010) J Autism Dev Disord , vol.40 , pp. 721-729
    • Kuhlthau, K.1    Orlich, F.2    Hall, T.A.3    Sikora, D.4    Kovacs, E.A.5    Delahaye, J.6
  • 12
    • 54049103639 scopus 로고    scopus 로고
    • Prevalence and risk factors of maladaptive behaviour in young children with autistic disorder
    • Hartley S.L., Sikora D.M., McCoy R. Prevalence and risk factors of maladaptive behaviour in young children with autistic disorder. J Intellect Disabil Res 2008, 52:819-829.
    • (2008) J Intellect Disabil Res , vol.52 , pp. 819-829
    • Hartley, S.L.1    Sikora, D.M.2    McCoy, R.3
  • 13
    • 77954934909 scopus 로고    scopus 로고
    • Effectiveness of medication combined with intensive behavioral intervention for reducing aggression in youth with autism spectrum disorder
    • Frazier T.W., Youngstrom E.A., Haycook T., Sinoff A., Dimitriou F., Knapp J., et al. Effectiveness of medication combined with intensive behavioral intervention for reducing aggression in youth with autism spectrum disorder. J Child Adolesc Psychopharmacol 2010, 20:167-177.
    • (2010) J Child Adolesc Psychopharmacol , vol.20 , pp. 167-177
    • Frazier, T.W.1    Youngstrom, E.A.2    Haycook, T.3    Sinoff, A.4    Dimitriou, F.5    Knapp, J.6
  • 14
    • 83055180252 scopus 로고    scopus 로고
    • High prescription drug use and associated costs among medicaid-eligible children with autism spectrum disorders identified by a population-based surveillance network
    • Logan S.L., Nicholas J.S., Carpenter L.A., King L.B., Garrett-Mayer E., Charles J.M. High prescription drug use and associated costs among medicaid-eligible children with autism spectrum disorders identified by a population-based surveillance network. Ann Epidemiol 2012, 22:1-8.
    • (2012) Ann Epidemiol , vol.22 , pp. 1-8
    • Logan, S.L.1    Nicholas, J.S.2    Carpenter, L.A.3    King, L.B.4    Garrett-Mayer, E.5    Charles, J.M.6
  • 16
    • 82055164151 scopus 로고    scopus 로고
    • Concurrent medical conditions and health care use and needs among children with learning and behavioral developmental disabilities, National Health Interview Survey, 2006-2010
    • Schieve L.A., Gonzalez V., Boulet S.L., Visser S.N., Rice C.E., Braun K.V., et al. Concurrent medical conditions and health care use and needs among children with learning and behavioral developmental disabilities, National Health Interview Survey, 2006-2010. Res Dev Disabil 2011, 33:467-476.
    • (2011) Res Dev Disabil , vol.33 , pp. 467-476
    • Schieve, L.A.1    Gonzalez, V.2    Boulet, S.L.3    Visser, S.N.4    Rice, C.E.5    Braun, K.V.6
  • 17
    • 77949426427 scopus 로고    scopus 로고
    • Epidemiology and management of insomnia in children with autistic spectrum disorders
    • Miano S., Ferri R. Epidemiology and management of insomnia in children with autistic spectrum disorders. Paediatr Drugs 2010, 12:75-84.
    • (2010) Paediatr Drugs , vol.12 , pp. 75-84
    • Miano, S.1    Ferri, R.2
  • 18
    • 79960957094 scopus 로고    scopus 로고
    • Melatonin in autism spectrum disorders: a systematic review and meta-analysis
    • Rossignol D.A., Frye R.E. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Dev Med Child Neurol 2011, 53:783-792.
    • (2011) Dev Med Child Neurol , vol.53 , pp. 783-792
    • Rossignol, D.A.1    Frye, R.E.2
  • 19
    • 84864335819 scopus 로고    scopus 로고
    • Melatonin for sleep in children with autism: a controlled trial examining dose, tolerability, and outcomes
    • Malow B., Adkins K.W., McGrew S.G., Wang L., Goldman S.E., Fawkes D., et al. Melatonin for sleep in children with autism: a controlled trial examining dose, tolerability, and outcomes. J Autism Dev Disord 2011, 10.1007/s10803-011-1418-3.
    • (2011) J Autism Dev Disord
    • Malow, B.1    Adkins, K.W.2    McGrew, S.G.3    Wang, L.4    Goldman, S.E.5    Fawkes, D.6
  • 20
    • 79955977714 scopus 로고    scopus 로고
    • Traditional and non-traditional treatments for autism spectrum disorder with seizures: an on-line survey
    • Frye R.E., Sreenivasula S., Adams J.B. Traditional and non-traditional treatments for autism spectrum disorder with seizures: an on-line survey. BMC Pediatr 2011, 11:37.
    • (2011) BMC Pediatr , vol.11 , pp. 37
    • Frye, R.E.1    Sreenivasula, S.2    Adams, J.B.3
  • 21
    • 79959846278 scopus 로고    scopus 로고
    • Aggression in children and adolescents with ASD: prevalence and risk factors
    • Kanne S.M., Mazurek M.O. Aggression in children and adolescents with ASD: prevalence and risk factors. J Autism Dev Disord 2011, 41:926-937.
    • (2011) J Autism Dev Disord , vol.41 , pp. 926-937
    • Kanne, S.M.1    Mazurek, M.O.2
  • 22
  • 23
    • 20044374710 scopus 로고    scopus 로고
    • Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology
    • McDougle C.J., Scahill L., Aman M.G., McCracken J.T., Tierney E., Davies M., et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 2005, 162:1142-1148.
    • (2005) Am J Psychiatry , vol.162 , pp. 1142-1148
    • McDougle, C.J.1    Scahill, L.2    Aman, M.G.3    McCracken, J.T.4    Tierney, E.5    Davies, M.6
  • 24
    • 33746053489 scopus 로고    scopus 로고
    • Risperidone in children with autism: randomized, placebo-controlled, double-blind study
    • Nagaraj R., Singhi P., Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol 2006, 21:450-455.
    • (2006) J Child Neurol , vol.21 , pp. 450-455
    • Nagaraj, R.1    Singhi, P.2    Malhi, P.3
  • 25
    • 33847221134 scopus 로고    scopus 로고
    • Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial
    • Pandina G.J., Bossie C.A., Youssef E., Zhu Y., Dunbar J. Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 2007, 37:367-373.
    • (2007) J Autism Dev Disord , vol.37 , pp. 367-373
    • Pandina, G.J.1    Bossie, C.A.2    Youssef, E.3    Zhu, Y.4    Dunbar, J.5
  • 27
    • 33846562907 scopus 로고    scopus 로고
    • Effects of short- and long-term risperidone treatment on prolactin levels in children with autism
    • Anderson G.M., Scahill L., McCracken J.T., McDougle C.J., Aman M.G., Tierney E., et al. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry 2007, 61:545-550.
    • (2007) Biol Psychiatry , vol.61 , pp. 545-550
    • Anderson, G.M.1    Scahill, L.2    McCracken, J.T.3    McDougle, C.J.4    Aman, M.G.5    Tierney, E.6
  • 28
    • 71449095638 scopus 로고    scopus 로고
    • A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder
    • Marcus R.N., Owen R., Kamen L., Manos G., McQuade R.D., Carson W.H., et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 2009, 48:1110-1119.
    • (2009) J Am Acad Child Adolesc Psychiatry , vol.48 , pp. 1110-1119
    • Marcus, R.N.1    Owen, R.2    Kamen, L.3    Manos, G.4    McQuade, R.D.5    Carson, W.H.6
  • 29
    • 71949121464 scopus 로고    scopus 로고
    • Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder
    • Owen R., Sikich L., Marcus R.N., Corey-Lisle P., Manos G., McQuade R.D., et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 2009, 124:1533-1540.
    • (2009) Pediatrics , vol.124 , pp. 1533-1540
    • Owen, R.1    Sikich, L.2    Marcus, R.N.3    Corey-Lisle, P.4    Manos, G.5    McQuade, R.D.6
  • 30
    • 79958786682 scopus 로고    scopus 로고
    • Aripiprazole in the treatment of irritability in pediatric patients (aged 6-17 years) with autistic disorder: results from a 52-week, open-label study
    • Marcus R.N., Owen R., Manos G., Mankoski R., Kamen L., McQuade R.D., et al. Aripiprazole in the treatment of irritability in pediatric patients (aged 6-17 years) with autistic disorder: results from a 52-week, open-label study. J Child Adolesc Psychopharmacol 2011, 21:229-236.
    • (2011) J Child Adolesc Psychopharmacol , vol.21 , pp. 229-236
    • Marcus, R.N.1    Owen, R.2    Manos, G.3    Mankoski, R.4    Kamen, L.5    McQuade, R.D.6
  • 31
    • 79955600656 scopus 로고    scopus 로고
    • Retrospective review of clozapine in the treatment of patients with autism spectrum disorder and severe disruptive behaviors
    • Beherec L., Lambrey S., Quilici G., Rosier A., Falissard B., Guillin O. Retrospective review of clozapine in the treatment of patients with autism spectrum disorder and severe disruptive behaviors. J Clin Psychopharmacol 2011, 31:341-344.
    • (2011) J Clin Psychopharmacol , vol.31 , pp. 341-344
    • Beherec, L.1    Lambrey, S.2    Quilici, G.3    Rosier, A.4    Falissard, B.5    Guillin, O.6
  • 34
    • 76749085678 scopus 로고    scopus 로고
    • Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders
    • Hollander E., Chaplin W., Soorya L., Wasserman S., Novotny S., Rusoff J., et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology 2010, 35:990-998.
    • (2010) Neuropsychopharmacology , vol.35 , pp. 990-998
    • Hollander, E.1    Chaplin, W.2    Soorya, L.3    Wasserman, S.4    Novotny, S.5    Rusoff, J.6
  • 36
    • 8144227746 scopus 로고    scopus 로고
    • A retrospective assessment of topiramate in children and adolescents with pervasive developmental disorders
    • Hardan A.Y., Jou R.J., Handen B.L. A retrospective assessment of topiramate in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2004, 14:426-432.
    • (2004) J Child Adolesc Psychopharmacol , vol.14 , pp. 426-432
    • Hardan, A.Y.1    Jou, R.J.2    Handen, B.L.3
  • 37
    • 33749236065 scopus 로고    scopus 로고
    • Topiramate in children with autistic spectrum disorders
    • Mazzone L., Ruta L. Topiramate in children with autistic spectrum disorders. Brain Dev 2006, 28:668.
    • (2006) Brain Dev , vol.28 , pp. 668
    • Mazzone, L.1    Ruta, L.2
  • 40
    • 0035321893 scopus 로고    scopus 로고
    • Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial
    • Belsito K.M., Law P.A., Kirk K.S., Landa R.J., Zimmerman A.W. Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 2001, 31:175-181.
    • (2001) J Autism Dev Disord , vol.31 , pp. 175-181
    • Belsito, K.M.1    Law, P.A.2    Kirk, K.S.3    Landa, R.J.4    Zimmerman, A.W.5
  • 42
    • 84555189923 scopus 로고    scopus 로고
    • Prevalence and correlates of psychotropic medication use in adolescents with an autism spectrum disorder with and without caregiver-reported attention-deficit/hyperactivity disorder
    • Frazier T.W., Shattuck P.T., Narendorf S.C., Cooper B.P., Wagner M., Spitznagel E.L. Prevalence and correlates of psychotropic medication use in adolescents with an autism spectrum disorder with and without caregiver-reported attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2011, 21:571-579.
    • (2011) J Child Adolesc Psychopharmacol , vol.21 , pp. 571-579
    • Frazier, T.W.1    Shattuck, P.T.2    Narendorf, S.C.3    Cooper, B.P.4    Wagner, M.5    Spitznagel, E.L.6
  • 43
    • 33845749041 scopus 로고    scopus 로고
    • Drug therapy for attention deficit/ hyperactivity disorder-like symptoms in autistic disorder
    • Hazell P. Drug therapy for attention deficit/ hyperactivity disorder-like symptoms in autistic disorder. J Paediatr Child Health 2007, 43:19-24.
    • (2007) J Paediatr Child Health , vol.43 , pp. 19-24
    • Hazell, P.1
  • 44
    • 3342976049 scopus 로고    scopus 로고
    • Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study
    • Di Martino A., Melis G., Cianchetti C., Zuddas A. Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study. J Child Adolesc Psychopharmacol 2004, 14:207-218.
    • (2004) J Child Adolesc Psychopharmacol , vol.14 , pp. 207-218
    • Di Martino, A.1    Melis, G.2    Cianchetti, C.3    Zuddas, A.4
  • 45
    • 27744466024 scopus 로고    scopus 로고
    • Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity
    • Research Units on Pediatric Psychopharmacology Autism Network
    • Research Units on Pediatric Psychopharmacology Autism Network Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 2005, 62:1266-1274.
    • (2005) Arch Gen Psychiatry , vol.62 , pp. 1266-1274
  • 46
    • 59849097573 scopus 로고    scopus 로고
    • Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity
    • Jahromi L., Kasari C.L., McCracken J.T., Lee L.S., Aman M.G., McDougle C.J., et al. Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. J Autism Dev Disord 2009, 39:395-404.
    • (2009) J Autism Dev Disord , vol.39 , pp. 395-404
    • Jahromi, L.1    Kasari, C.L.2    McCracken, J.T.3    Lee, L.S.4    Aman, M.G.5    McDougle, C.J.6
  • 47
    • 33846643952 scopus 로고    scopus 로고
    • Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures
    • Posey D.J., Aman M.G., McCracken J.T., Scahill L., Tierney E., Arnold L.E., et al. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. Biol Psychiatry 2007, 61:538-544.
    • (2007) Biol Psychiatry , vol.61 , pp. 538-544
    • Posey, D.J.1    Aman, M.G.2    McCracken, J.T.3    Scahill, L.4    Tierney, E.5    Arnold, L.E.6
  • 48
    • 33750944897 scopus 로고    scopus 로고
    • Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders
    • Posey D.J., Wiegand R.E., Wilkerson J., Maynard M., Stigler K.A., McDougle C.J. Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006, 16:599-610.
    • (2006) J Child Adolesc Psychopharmacol , vol.16 , pp. 599-610
    • Posey, D.J.1    Wiegand, R.E.2    Wilkerson, J.3    Maynard, M.4    Stigler, K.A.5    McDougle, C.J.6
  • 49
    • 82455167368 scopus 로고    scopus 로고
    • Efficacy of atomoxetine in children with severe autistic disorders and symptoms of ADHD: an open-label study
    • Charnsil C. Efficacy of atomoxetine in children with severe autistic disorders and symptoms of ADHD: an open-label study. J Atten Disord 2011, 15:684-689.
    • (2011) J Atten Disord , vol.15 , pp. 684-689
    • Charnsil, C.1
  • 51
    • 80051878678 scopus 로고    scopus 로고
    • Response to atomoxetine in boys with high-functioning autism spectrum disorders and attention deficit/hyperactivity disorder
    • Zeiner P., Gjevik E., Weidle B. Response to atomoxetine in boys with high-functioning autism spectrum disorders and attention deficit/hyperactivity disorder. Acta Paediatr 2011, 100:1258-1261.
    • (2011) Acta Paediatr , vol.100 , pp. 1258-1261
    • Zeiner, P.1    Gjevik, E.2    Weidle, B.3
  • 53
    • 51249117402 scopus 로고    scopus 로고
    • Guanfacine in children with autism and/or intellectual disabilities
    • Handen B.L., Sahl R., Hardan A.Y. Guanfacine in children with autism and/or intellectual disabilities. J Dev Behav Pediatr 2008, 29:303-308.
    • (2008) J Dev Behav Pediatr , vol.29 , pp. 303-308
    • Handen, B.L.1    Sahl, R.2    Hardan, A.Y.3
  • 54
    • 77249163833 scopus 로고    scopus 로고
    • Possible influence of variant of the P-glycoprotein gene (MDR1/ABCB1) on clinical response to guanfacine in children with pervasive developmental disorders and hyperactivity
    • McCracken J.T., Aman M.G., McDougle C.J., Tierney E., Shiraga S., Whelan F., et al. Possible influence of variant of the P-glycoprotein gene (MDR1/ABCB1) on clinical response to guanfacine in children with pervasive developmental disorders and hyperactivity. J Child Adolesc Psychopharmacol 2010, 20:1-5.
    • (2010) J Child Adolesc Psychopharmacol , vol.20 , pp. 1-5
    • McCracken, J.T.1    Aman, M.G.2    McDougle, C.J.3    Tierney, E.4    Shiraga, S.5    Whelan, F.6
  • 55
  • 56
    • 45949091139 scopus 로고    scopus 로고
    • Use of clonidine in children with autism spectrum disorders
    • Ming X., Gordon E., Kang N., Wagner G.C. Use of clonidine in children with autism spectrum disorders. Brain Dev 2008, 30:454-460.
    • (2008) Brain Dev , vol.30 , pp. 454-460
    • Ming, X.1    Gordon, E.2    Kang, N.3    Wagner, G.C.4
  • 57
    • 67650915116 scopus 로고    scopus 로고
    • Review of the evidence for treatment of children with autism with selective serotonin reuptake inhibitors
    • West L., Brunssen S.H., Waldrop J. Review of the evidence for treatment of children with autism with selective serotonin reuptake inhibitors. J Spec Pediatr Nurs 2009, 14:183-191.
    • (2009) J Spec Pediatr Nurs , vol.14 , pp. 183-191
    • West, L.1    Brunssen, S.H.2    Waldrop, J.3
  • 58
    • 84893391547 scopus 로고    scopus 로고
    • Selective serotonin reuptake inhibitors (SSRI) for autism spectrum disorders (ASD)
    • Williams K, Wheeler DM, Silove N, Hazell P. Selective serotonin reuptake inhibitors (SSRI) for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2010; 8:CD004677.
    • (2010) Cochrane Database Syst Rev , vol.8
    • Williams, K.1    Wheeler, D.M.2    Silove, N.3    Hazell, P.4
  • 59
    • 13944264748 scopus 로고    scopus 로고
    • A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism
    • Hollander E., Phillips A., Chaplin W., Zagursky K., Novotny S., Wasserman S., et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 2005, 30:582-589.
    • (2005) Neuropsychopharmacology , vol.30 , pp. 582-589
    • Hollander, E.1    Phillips, A.2    Chaplin, W.3    Zagursky, K.4    Novotny, S.5    Wasserman, S.6
  • 60
    • 84858971972 scopus 로고    scopus 로고
    • A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders
    • Hollander E., Soorya L., Chaplin W., Anagnostou E., Taylor B.P., Ferretti C.J., et al. A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. Am J Psychiatry 2011, 10.1176/appi.ajp. 2011.10050764.
    • (2011) Am J Psychiatry
    • Hollander, E.1    Soorya, L.2    Chaplin, W.3    Anagnostou, E.4    Taylor, B.P.5    Ferretti, C.J.6
  • 61
    • 66449098701 scopus 로고    scopus 로고
    • Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism
    • King B.H., Hollander E., Sikich L., McCracken J.T., Scahill L., Bregman J.D., et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry 2009, 66:583-590.
    • (2009) Arch Gen Psychiatry , vol.66 , pp. 583-590
    • King, B.H.1    Hollander, E.2    Sikich, L.3    McCracken, J.T.4    Scahill, L.5    Bregman, J.D.6
  • 63
    • 77249129027 scopus 로고    scopus 로고
    • A pharmacogenetic study of escitalopram in autism spectrum disorders
    • Owley T., Brune C.W., Salt J., Walton L., Guter S., Ayuyao N., et al. A pharmacogenetic study of escitalopram in autism spectrum disorders. Autism Res 2010, 3:1-7.
    • (2010) Autism Res , vol.3 , pp. 1-7
    • Owley, T.1    Brune, C.W.2    Salt, J.3    Walton, L.4    Guter, S.5    Ayuyao, N.6
  • 64
    • 84864781015 scopus 로고    scopus 로고
    • Evaluation of the GABAergic nervous system in autistic brain: (123) I-iomazenil SPECT study
    • Mori T., Mori K., Fujii E., Toda Y., Miyazaki M., Harada M., et al. Evaluation of the GABAergic nervous system in autistic brain: (123) I-iomazenil SPECT study. Brain Dev 2012, 34:648-654.
    • (2012) Brain Dev , vol.34 , pp. 648-654
    • Mori, T.1    Mori, K.2    Fujii, E.3    Toda, Y.4    Miyazaki, M.5    Harada, M.6
  • 65
    • 84855528326 scopus 로고    scopus 로고
    • Glutamate mediated signaling in the pathophysiology of autism spectrum disorders
    • Choudhury P.R., Lahiri S., Rajamma U. Glutamate mediated signaling in the pathophysiology of autism spectrum disorders. Pharmacol Biochem Behav 2011, 10.1016/j.pbb.2011.06.023.
    • (2011) Pharmacol Biochem Behav
    • Choudhury, P.R.1    Lahiri, S.2    Rajamma, U.3
  • 66
    • 77953028667 scopus 로고    scopus 로고
    • The neuropathology of autism: defects of neurogenesis and neuronal migration, and dysplastic changes
    • Wegiel J., Kuchna I., Nowicki K., Imaki H., Wegiel J., Marchi E., et al. The neuropathology of autism: defects of neurogenesis and neuronal migration, and dysplastic changes. Acta Neuropathol 2010, 119:755-770.
    • (2010) Acta Neuropathol , vol.119 , pp. 755-770
    • Wegiel, J.1    Kuchna, I.2    Nowicki, K.3    Imaki, H.4    Wegiel, J.5    Marchi, E.6
  • 67
    • 84856092811 scopus 로고    scopus 로고
    • Networking in autism: leveraging genetic, biomarker and model system findings in the search for new treatments
    • Veenstra-Vanderweele J., Blakely R.D. Networking in autism: leveraging genetic, biomarker and model system findings in the search for new treatments. Neuropsychopharmacology 2012, 37:196-212.
    • (2012) Neuropsychopharmacology , vol.37 , pp. 196-212
    • Veenstra-Vanderweele, J.1    Blakely, R.D.2
  • 68
    • 48449088655 scopus 로고    scopus 로고
    • Treatment of autism spectrum disorders: neurotransmitter signaling pathways involved in motivation and reward as therapeutic targets
    • Walker M.A. Treatment of autism spectrum disorders: neurotransmitter signaling pathways involved in motivation and reward as therapeutic targets. Expert Opin Ther Targets 2008, 12:949-967.
    • (2008) Expert Opin Ther Targets , vol.12 , pp. 949-967
    • Walker, M.A.1
  • 69
  • 70
    • 57149111476 scopus 로고    scopus 로고
    • Effects of risperidone on cognitive-motor performance and motor movements in chronically medicated children
    • Aman M.G., Hollway J.A., Leone S., Masty J., Lindsay R., Nash P., et al. Effects of risperidone on cognitive-motor performance and motor movements in chronically medicated children. Res Dev Disabil 2009, 30:386-396.
    • (2009) Res Dev Disabil , vol.30 , pp. 386-396
    • Aman, M.G.1    Hollway, J.A.2    Leone, S.3    Masty, J.4    Lindsay, R.5    Nash, P.6
  • 73
    • 79956155995 scopus 로고    scopus 로고
    • Pre- and post-treatments with escitalopram protect against experimental ischemic neuronal damage via regulation of BDNF expression and oxidative stress
    • Lee C.H., Park J.H., Yoo K.Y., Choi J.H., Hwang I.K., Ryu P.D., et al. Pre- and post-treatments with escitalopram protect against experimental ischemic neuronal damage via regulation of BDNF expression and oxidative stress. Exp Neurol 2011, 229:450-459.
    • (2011) Exp Neurol , vol.229 , pp. 450-459
    • Lee, C.H.1    Park, J.H.2    Yoo, K.Y.3    Choi, J.H.4    Hwang, I.K.5    Ryu, P.D.6
  • 74
    • 78149431869 scopus 로고    scopus 로고
    • Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes
    • Chao H.T., Chen H., Samaco R.C., Xue M., Chahrour M., Yoo J., et al. Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature 2010, 468:263-269.
    • (2010) Nature , vol.468 , pp. 263-269
    • Chao, H.T.1    Chen, H.2    Samaco, R.C.3    Xue, M.4    Chahrour, M.5    Yoo, J.6
  • 75
    • 33846238191 scopus 로고    scopus 로고
    • Major defects in neocortical GABAergic inhibitory circuits in mice lacking the fragile X mental retardation protein
    • Selby L., Zhang C., Sun Q.Q. Major defects in neocortical GABAergic inhibitory circuits in mice lacking the fragile X mental retardation protein. Neurosci Lett 2007, 412:227-232.
    • (2007) Neurosci Lett , vol.412 , pp. 227-232
    • Selby, L.1    Zhang, C.2    Sun, Q.Q.3
  • 76
    • 79651475390 scopus 로고    scopus 로고
    • Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders
    • Ehninger D., Silva A.J. Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders. Trends Mol Med 2011, 17:78-87.
    • (2011) Trends Mol Med , vol.17 , pp. 78-87
    • Ehninger, D.1    Silva, A.J.2
  • 77
    • 80053583200 scopus 로고    scopus 로고
    • Genetics and function of neocortical GABAergic interneurons in neurodevelopmental disorders
    • Rossignol E. Genetics and function of neocortical GABAergic interneurons in neurodevelopmental disorders. Neural Plast 2011, 2011:649325.
    • (2011) Neural Plast , vol.2011 , pp. 649325
    • Rossignol, E.1
  • 78
    • 77956227931 scopus 로고    scopus 로고
    • Autism spectrum disorders and epilepsy: moving towards a comprehensive approach to treatment
    • Tuchman R., Alessandri M., Cuccaro M. Autism spectrum disorders and epilepsy: moving towards a comprehensive approach to treatment. Brain Dev 2010, 32:719-730.
    • (2010) Brain Dev , vol.32 , pp. 719-730
    • Tuchman, R.1    Alessandri, M.2    Cuccaro, M.3
  • 79
    • 80053273580 scopus 로고    scopus 로고
    • Complex effects of mGluR5 antagonism on sociability and stereotypic behaviors in mice. Possible implications for the pharmacotherapy of autism spectrum disorders
    • Burket J.A., Herndon A.L., Winebarger E.E., Jacome L.F., Deutsch S.I. Complex effects of mGluR5 antagonism on sociability and stereotypic behaviors in mice. Possible implications for the pharmacotherapy of autism spectrum disorders. Brain Res Bull 2011, 86:152-158.
    • (2011) Brain Res Bull , vol.86 , pp. 152-158
    • Burket, J.A.1    Herndon, A.L.2    Winebarger, E.E.3    Jacome, L.F.4    Deutsch, S.I.5
  • 81
    • 14344267755 scopus 로고    scopus 로고
    • Double-blind, placebo-controlled study of amantidine hydrochloride in the treatment of children with autistic disorder
    • King B.H., Wright D.M., Handen B.L., Sikich L., Zimmerman A.W., McMahon W., et al. Double-blind, placebo-controlled study of amantidine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry 2001, 40:658-665.
    • (2001) J Am Acad Child Adolesc Psychiatry , vol.40 , pp. 658-665
    • King, B.H.1    Wright, D.M.2    Handen, B.L.3    Sikich, L.4    Zimmerman, A.W.5    McMahon, W.6
  • 82
    • 77954944264 scopus 로고    scopus 로고
    • Autism and oxytocin: new developments in translational approaches to therapeutics
    • Green J.J., Hollander E. Autism and oxytocin: new developments in translational approaches to therapeutics. Neurotherapeutics 2010, 7:250-257.
    • (2010) Neurotherapeutics , vol.7 , pp. 250-257
    • Green, J.J.1    Hollander, E.2
  • 84
    • 0642273081 scopus 로고    scopus 로고
    • Evidence-based treatments in child and adolescent psychiatry: an inventory
    • McClellan J.M., Werry J.S. Evidence-based treatments in child and adolescent psychiatry: an inventory. J Am Acad Child Adolesc Psychiatry 2003, 42:1388-1400.
    • (2003) J Am Acad Child Adolesc Psychiatry , vol.42 , pp. 1388-1400
    • McClellan, J.M.1    Werry, J.S.2
  • 85
    • 72949098166 scopus 로고    scopus 로고
    • Altered calcium homeostasis in autism-spectrum disorders: evidence from biochemical and genetic studies of the mitochondrial aspartate/glutamate carrier AGC1
    • Palmieri L., Papaleo V., Porcelli V., Scarcia P., Gaita L., Sacco R., et al. Altered calcium homeostasis in autism-spectrum disorders: evidence from biochemical and genetic studies of the mitochondrial aspartate/glutamate carrier AGC1. Mol Psychiatry 2010, 15:38-52.
    • (2010) Mol Psychiatry , vol.15 , pp. 38-52
    • Palmieri, L.1    Papaleo, V.2    Porcelli, V.3    Scarcia, P.4    Gaita, L.5    Sacco, R.6
  • 86
    • 79951614797 scopus 로고    scopus 로고
    • Can ziconotide as a N-type voltage-sensitive calcium channel blocker open a new mode for treatment of autism? A hypothesis
    • Ghanizadeh A. Can ziconotide as a N-type voltage-sensitive calcium channel blocker open a new mode for treatment of autism? A hypothesis. Neurosciences 2011, 16:83.
    • (2011) Neurosciences , vol.16 , pp. 83
    • Ghanizadeh, A.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.